Mackenzie Financial’s Avidity Biosciences RNAM Stock Holding History

Mackenzie Financial’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,255	Closed	-$522K	–	1703
2025 Q4	$522K	Buy	7,255 +941	+15%	+$60.8K	﹤0.01%	1212
2025 Q3	$275K	Sell	6,314 -1,023	-14%	-$41.4K	﹤0.01%	1454
2025 Q2	$208K	Buy	7,337 +132	+2%	+$3.93K	﹤0.01%	1544
2025 Q1	$213K	Buy	+7,205	New	+$224K	﹤0.01%	1497
2024 Q4	–	Sell	-6,530	Closed	-$300K	–	1777
2024 Q3	$300K	Buy	+6,530	New	+$283K	﹤0.01%	1191

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

Mackenzie Financial's RNAM Position: Q1 2026 in Review

Mackenzie Financial sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 7,255 shares — an estimated $522K sold.

Mackenzie Financial first reported a position in RNAM in Q3 2024 and held it in 5 quarters. The position peaked at $522K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Mackenzie Financial reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Mackenzie Financial sold 7,255 Avidity Biosciences shares in Q1 2026, an estimated $522K.
Mackenzie Financial first reported a position in Avidity Biosciences in Q3 2024 and held it in 5 quarters.
Mackenzie Financial's Avidity Biosciences position peaked at $522K in Q4 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.